CD8A and hepatocellular carcinoma: Our findings thus suggest that aldometanib, by causing metabolic changes that improve the microenvironment within the host tissues and/or the microenvironment between the tumor tissue and para-tumor tissue, does not rely on these cytokines to promote the infiltration of CD8+ T cells into HCC.